Category: IHC-Antibodies

Specification:

Mutations within the BRCA1 gene, localized to chromosome 17q, are believed to account for approximately 45% of families with increased incidence of both early-onset breast cancer and ovarian cancer. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1,863 amino acids. This protein contains a RING domain near the N-terminus and appears to encode a tumor suppressor. BARD1 (BRCA1-associated RING domain protein 1) and BAP1 (BRCA1-associated protein 1) have both been shown to bind to the N-terminus of BRCA1 and are potential mediators of tumor suppression. BARD1 contains an N-terminal RING domain and three tandem ankyrin repeats. The C terminus of BARD1 contains a region with sequence homology to BRCA1, termed the BRCT domain. BAP1 is a ubiquitin hydrolase and has been shown to enhance BRCA1-mediated cell growth suppression.

Immunogen:

Amino acids 430-729 of BAP1 of human origin

Presentation:

Antibody in PBS with < 0.1% sodium azide and 0.1% gelatin

Specification:

This antibody reacts primarily with gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is useful in the differentiation of specific types of simple epithelial cells of the urinary tract as well as normal and malignantly transformed epithelia. Studies have identified the presence of Cytokeratin 20 in adenocarcinomas of the colon, stomach, pancreas and biliary system. Additionally, mucinous ovarian tumors, transitional-cell and Merkel cell carcinomas have shown reactivity. In contrast, squamous cell carcinomas and adenocarcinomas of the breast, lung and endometrium, non-mucinous tumors of the ovary, and small cell carcinomas are non-reactive.

Presentation:

Anti-Cytokeratin 20 is a mouse monoclonal antibody from supernatant diluted in tris buffered saline, pH 7.3
7.7, with protein base, and preserved with sodium azide

Specification:

Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large Bcell lymphomas(DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes.(3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (“L&H”) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Immunogen:

Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary)

Presentation:

Purified antibody diluted in Tris-HCI buffer containing stabilizing protein and <0.1% sodium Azide.

Specification:

Anti-Lambda detects surface immunoglobulin on normal and neoplastic B-cells. Lambda staining is seen in B-cell follicles of human lymphoid tissue. When dealing with B-cell neoplasms, the determination of light chain ratios remains the centerpiece. This is sound reasoning because most B-cell lymphomas express either kappa or lambda light chains, whereas reactive proliferations display a mixture of kappa and lambda positive cells. If only a single light chain type is detected, a lymphoproliferative disorder is very likely. Monoclonality is determined by a kappa-lambda ratio of greater than or equal to 3:1, a lambda-kappa ratio greater than or equal to 2:1 or a monoclonal population of 75% or more of the total population.

Presentation:

Anti-Lambda is a mouse monoclonal antibody from supernatant diluted in tris buffered saline, pH 7.3-7.7, with protein base, and preserved with sodium azide.

Specification:

The p63 gene is located at chromosome 3q27-29 and belongs to the p53 gene family. p63 plays a critical role in the growth and development of many epithelial organs. p63 is confined to basal cells of squamous epithelia (including epidermis and hair follicles) and urothelium, as well as basal cells/myoepithelial cells in breast, sweat glands, salivary glands, and prostate. The expression of p63 has clinical value as a diagnostic marker in various tumor types. Thus, p63 helps to distinguish squamous cell carcinoma from adenocarcinoma in the lung or urothelial carcinoma from renal cell carcinoma. As known marker of basal cells in breast and prostate, p63 expression is useful for prostate cancer diagnosis and identifies a basal phenotype in some breast carcinomas.

Presentation:

tissue culture supernatant with 15mM sodium azide